CERS News and Press, Cerus Corporation From 11/03/22

Cerus Corporation (CERS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 P.M. ET Company Participants Jessica Hanover - Vice President, Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kev...

Cerus press release ( NASDAQ: CERS ): Q3 GAAP EPS of -$0.05 beats by $0.01 . Revenue of $46.34M (+10.1% Y/Y) beats by $6.22M . The Company expects full-year 2022 product revenue to be in the range of $160 million to $162 million, compared to its previous guidan...

Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 202...

$9.1 million funding to support manufacturing scale-up and defining pathway for FDA registration for DoD and civilian use Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded a $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base...

Cerus ( NASDAQ: CERS ) on Tuesday said Canada's drug regulator had approved extending the storage of platelets treated with the company's blood system from five days to seven days from the time of collection. CERS' INTERCEPT Blood System is used to reduce pathogens in plat...

Extended Shelf Life Reflects Important Milestone toward Expanding Nationwide Footprint in Canada Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from fi...

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Summary Cerus Corporation continues to incur heavy downside in FY22 despite showing technical support earlier in the year. Shares have now broken key support levels and without any change to the fundamental picture, the investment case weakens further. Long-duration equities s...

Workshop and Abstracts Highlight the Favorable Impacts Associated with the INTERCEPT Blood System for Platelets and the INTERCEPT Blood System for Cryoprecipitation in Clinical Settings Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry ...